at the CHU Sainte-Justine/
Université de Montréal
Clinical and scientific studies to understand and discover new treatments for Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS).
The ME / CFS Collaborative Research Center, established in 2020 at CHU Sainte-Justine /Université de Montréal, increases OMF’s international collaborative efforts through the End ME/CFS Project. Directed by Alain Moreau, PhD, the Quebec, Canada-based laboratory has been researching ME / CFS for several years.
Alain Moreau, PhD, is a Full Professor in the Department of Stomatology, Faculty of Dentistry and Department of Biochemistry and Molecular Medicine, Faculty of Medicine, at Université de Montréal, Montréal, Québec, Canada. Additionally, Dr. Moreau is the Director of Network for Canadian Oral Health Research. He is the Scientific Director of the Viscogliosi Laboratory in Molecular Genetics of Musculoskeletal Diseases, Sainte-Justine University Research Center, Montréal, Québec.
Dr. Moreau’s chief interests of study are pediatric scoliosis, osteoarthritis, osteoporosis, and Myalgic Encephalomyelitis. Dr. Moreau is a member of the Open Medicine Foundation Scientific Advisory Board and is the Director of the Interdisciplinary Canadian Collaborative Myalgic Encephalomyelitis Research Network, a national research network funded by the Canadian Institute of Health Research.
the pathophysiology of ME/CFS, especially on severely affected persons
a molecular diagnostic test
a multi-omic approach to better stratify patients
molecular profiling of discordant and concordant twins with ME/CFS
multigenerational families affected by ME/CFS
possible treatment plans
The overarching goal of RASPBERRY-ME project is the characterization of the biomolecular signature of Myalgic Encephalomyelitis using Label-free Raman Spectroscopy (RS) and machine learning models.
The purpose of this study is to capture a post-COVID-19 infected population willing to participate in phenotyping studies early in the post-COVID-19 illness progression, with an aim of providing targeted effective therapies and preventing the onset and progression of ME/CFS.
The primary goal of this project is to complete our comprehensive analysis of the genome, methylome, miRnome, and their interactions in order to fill the gaps in our understanding of ME/CFS pathophysiology and to identify clinically useful biomarkers.
The overarching goal of RASPBERRY-ME project is the characterization of the biomolecular signature of Myalgic Encephalomyelitis using Label-free Raman Spectroscopy (RS) and machine learning models.
The purpose of this study is to capture a post-COVID-19 infected population willing to participate in phenotyping studies early in the post-COVID-19 illness progression, with an aim of providing targeted effective therapies and preventing the onset and progression of ME/CFS.
The primary goal of this project is to complete our comprehensive analysis of the genome, methylome, miRnome, and their interactions in order to fill the gaps in our understanding of ME/CFS pathophysiology and to identify clinically useful biomarkers.
The REMEDIAL project continues the work commenced with MAESTRO and will lead to a better understanding of the molecular mechanisms underlying ME/CFS pathophysiology, the persistence and variability of the symptoms, and will contribute to the identification of targets and therapeutic agents for intervention.
Researchers are actively working to understand the role of Thrombospondin-1, an important biomarker, in those with ME/CFS.
Studying microRNAs could help to bridge the conceptual gap between genetic predisposition and environmental factors causing ME/CFS or exacerbating specific symptoms.
Deep Proteome and Metabolome Profiling Study AIM Collaborate with OMF CRCs in Uppsala and Melbourne to establish a global perspective. Decode the molecular mechanisms underlying
CHU Sainte-Justine Research Center
Université de Montréal
Alain Moreau, PhD , Scientific Director
Anita Franco, MSc, Lab coordinator
Dashen Wang, MD, PhD, Research Associate
Mohamed Elbakry, PhD , Research Associate
Viorica Lascau, MSc , Research coordinator – certification manager
Sophie Perreault, RN , Clinical research nurse
Valerie Tremblay, RN, Clinical research nurse
Hélène Gagnon, RN, Clinical research nurse
Iurie Caraus, PhD , Postdoctoral fellow
Wesam Elremaly, PhD, Postdoctoral fellow
Lynda Chalder, MSc, PhD student
Evguenia Nepotchatykh, BSc, PhD student
Atefeh Moezzi, MSc, PhD student
Corinne Leveau, BSc, MSc student
Bita Rostami, BSc, MSc student
Marie-Yvonne Akoume PhD, Invited professor – ICanCME Research Network Investigator
Valérie Marcil PhD, Associate Professor – ICanCME Research Network Investigator
Emile Levy, MD, PhD ,Full Professor – ICanCME Research Network Investigator
University of Florida Atlantic
Dawei Li, PhD, Associated Professor – ICanCME Research Network Investigator
Jason Kost BSc , Research Assistant – ICanCME Research Network Member
Please help us expand our research efforts across the globe. Every donation brings us closer to a fully-funded research effort and the answers we all seek.
Open Medicine Foundation®
29302 Laro Drive, Agoura Hills, CA 91301 USA
Phone: 650-242-8669
Copyright © 2022 Open Medicine Foundation. All Rights Reserved.
What are the advantages of giving from your Donor Advised Fund (DAF)?
How do I make a donation through my DAF?
Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.
Still can’t find your fund?
Donate your appreciated stock directly to OMF and you can receive an immediate income-tax deduction for the fair market value of the securities on the date of transfer (even if you originally paid much less for them).Gifting of Stock
Broker: Schwab
DTC #: 0164
Account #: 47083887
Account Registered as:
Open Medicine Foundation
29302 Laro Drive
Agoura Hills, CA 91301
Please speak to your personal tax advisor and then call OMF at 650-242-8669 to notify us of your donation or with any questions.
